A new report released by Transparency Market Research forecasts a moderate 1.2% CAGR for the global osteoporosis drugs market between 2014 and 2020. According to the report, titled “Osteoporosis Drugs Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends & Forecast, 2014 - 2020”, the market valuation of osteoporosis drugs, which stood at US$8.4 billion in 2013, will exhibit steady growth to reach an estimated valuation of US$8.9 billion in 2020. Increasing incidence of osteoporosis has triggered concern globally. Osteoporosis is a chronic ailment in which bone density and bone mass is depleted to an extent that changes the bone microstructure and makes it more prone to cracks or fractures.

The enhanced threat of bone fracture and advent of new drug therapeutics are prime factors propelling the global osteoporosis drugs market. Osteoporosis is one of the rare classes of disease that can’t be treated with conventional methods such as surgery. Hence, drug administration is an inevitable inclusion in osteoporosis treatment.

The report is compiled with the prime intent of updating the stakeholders with the incumbent market dynamics. For a methodical appraisal, the report segments the osteoporosis drugs market on the basis of distinct drug classes administered during the treatment procedure. Among the schools of drugs most commonly used in osteoporosis treatment, bisphosphonates registered dominance with a 48.2% share in the market in 2013.However, the report predicts a slump in the growth trajectory of this class of drugs during the forecast period, due to repeated instances of chronic side effects from the consumption of the drugs. As a consequence of continued year-on-year decline in sales of Fosamax, the drug generating the highest revenue, the trajectory of the osteoporosis drugs market will plummet. However, the bisphosphonates class of drugs enjoys first mover advantage, which will ensure its dominant position in the osteoporosis market on account of revenue.

The SERM class of drugs, which held the second largest position in the market in 2013, will also encounter a strong impediment owing to the patent expiry of blockbuster drugs such as Evista in 2014. However, the report forecasts steady increase in demand for Vitamin D and calcium during the forecast period, since these are the best supplements during the prolonged osteoporosis treatment. Some of the novel osteoporosis drugs are at present under trial in both clinical and preclinical settings. The most prominent candidates in this line are Romosozumab, Odanacatib, and others. These drugs have already entered phase III of clinical trials. These drugs promise to provide better efficacy and have fewer side effects compared to the drugs available for osteoporosis treatment at present. The launch of new drugs, according to the report, is expected to boost the global osteoporosis market.

Request A Sample Of This Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=133


The report has identified that in 2013, North America led the global osteoporosis market. Factors such as high incidence of osteoporosis and change in dietary habits accentuated the demand for osteoporosis drugs in the region. However, steadily increasing patient pool of osteoporosis in Asia Pacific will give an incredible impetus to the osteoporosis drugs market in the region. Asia Pacific will thus register the fastest growth among the regional segments of the global osteoporosis drugs market. The global osteoporosis market is highly consolidated with only a handful of players enjoying the lion’s share. In 2013 the market was led by Eli Lilly and Company. Amgen, Inc. and Pfizer, Inc. collectively enjoyed the second largest market share. Other prominent leaders in the market include Novartis International AG and Merck, Inc.
The global osteoporosis drugs market is segmented as follows:
Global Osteoporosis Drugs Market, by Drugs Class:
• Bisphosphonates
• Calcitonin
• RANK Ligand Inhibitors
• Parathyroid Hormone Therapy (PTH)
• Selective Estrogen Receptor Modulators (SERMs)

Global Osteoporosis Drugs Market, by Geography:
• North America
• Europe
• Asia-Pacific
• Rest of the World (RoW)


About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact us:
Mr. Sudip S
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email:Â [email protected]
Website: http://www.transparencymarketresearch.com/